Cipla was founded in year 1935 as The Chemical, Industrial & Pharmaceutical Laboratories. It is a prominent Indian pharmaceutical company, which is market leader in respiratory segment with its brand Asthalin, cardiovascular disease, arthritis, diabetes, weight control, depression and in recent past has diversified into AIDS and HIN1 treatment. In early 1980's it persuaded than congress government to give relaxation in Indian patent law so that home grown generic companies could meet the domestic market demand, this helped many prescription based generic companies to expand internally and in global scenario. Cipla through this reform now has its global presence in more than 180 countries.Cipla this decade after GATT agreement follow up in Indian pharma scenario in year 2005 has shifted it focus on manufacturing generic version of drugs used for life threatening and pandemic diseases, In this scenario as its making life saving drugs cheaper version in one fourth of their original price it gets support of NGO's all over the world and world health organization, so that the originator companies cant pin point, I am very sure within 1 year it will launch its own generic version for treatment of H1N5.
At present Cipla has revenue worth approximately USD100 Billon and you can perhaps say it’s a highly profitable company with so called humanity touch , I think case studies should be prepared for how this small company went on to become top generic player in India and world with its very unique business model.
No comments:
Post a Comment